Specialty Pharmacy Management Software Problems: The 7 That Delay First Dose, and How to Avoid Them

Why does the project turn into replacing the dispensing system?

The characteristic scope failure here is deciding to rebuild dispensing. It follows an understandable logic. The dispensing system is where the pharmacy technically operates, it is where the claim adjudicates, and it is the thing people complain about. So the project becomes a replacement, and the budget disappears into claim adjudication, inventory and label printing, which are regulated, exacting and already solved.

The mistake is that specialty pharmacy is a coordination business where the drug leaves the building only at the end. The interval before it does, covering benefits investigation, prior authorisation, financial assistance, clinical assessment and shipment readiness, is the entire operational and commercial question, and no dispensing system was designed to see it as a connected process. It sees a prescription, a claim and a package.

The fix is to leave dispensing and claim adjudication in your existing system for the first phase and build the coordination layer around it. That is the single biggest scoping decision in the category and it changes the price band substantially. The first release should be referral intake, a unified patient therapy record, benefits and prior authorisation tracking, and a worklist ordered by days since referral with the current blocker named. That is a system your team works in all day, and it is where the value sits.

What goes wrong when you migrate patient, therapy and assistance history?

You are merging records from a dispensing system, a therapy management product, spreadsheets and several portals, and the join is harder than it looks because the entity you need did not exist in any of them. Nobody was storing this patient on this therapy as a single object with a start, a set of gates and a clock.

Four failures recur. The same patient appears on multiple therapies with no way to tell which clinical assessments belonged to which, so migrating assessments produces a record that is chronologically plausible and clinically misleading. Financial assistance sits in claim level adjustments rather than as tracked instruments, so remaining balances and expiry dates are simply not present in the source and cannot be reconstructed. Prior authorisation history exists as portal screenshots and faxes attached to nothing, so approval periods and expiry dates are unknown. And discontinuation reasons, which manufacturers ask for, were free text or absent.

The approach that works is to migrate the current state accurately and the history as reference. Active patients get a properly constructed therapy record with every gate reconstructed and verified by a pharmacist or coordinator, because those are the patients whose next fill depends on it. Historical fills and documents come across as attached reference clearly marked as pre migration. Re-verify active assistance and prior authorisation directly with the source rather than trusting an import, because a wrong expiry date on an active grant is exactly the error that pauses a therapy.

Why do hub, payer and dispensing integrations break after launch?

They break because most of them are not integrations. Genuine electronic paths exist for some payers and some manufacturers, and for the rest your team is logging into a portal, and any design that treats portal work as a temporary gap will fail as soon as volume grows.

The specific break is state drift. A prior authorisation is approved in a payer portal, the coordinator who checked it is off sick, and your system still shows it pending, so the patient sits in a queue that is now wrong. The mirror case is worse: an authorisation lapses and nothing notices because the expiry lived in the portal rather than in your record.

Two fixes worth insisting on. Model the manual paths explicitly, with a check task, an owner, a due date and a recorded outcome, so portal work is visible and measurable rather than invisible and assumed. And treat every gate as having its own validity period with re-verification scheduled before the next fill rather than annually, so lapses surface as work weeks in advance. On the dispensing side, the integration that matters is fill events flowing into the therapy record, because those events drive assessment scheduling and adherence measures. Ask any developer which dispensing system you run before they answer anything else, because that answer changes the shape of the work.

What happens when assistance tracking and accreditation evidence are not covered?

You get therapy interruptions that were entirely predictable and an accreditation cycle that consumes weeks of senior time. Both are quiet failures that never appear in a business case until they happen.

Financial assistance is the sharper one. A commercially insured patient may use a manufacturer copay card with an annual maximum. A government insured patient cannot, and needs a foundation grant that can exhaust mid year or a manufacturer patient assistance programme. Payer accumulator and maximiser programmes change how much of that assistance counts toward the deductible, which changes what the patient owes at the next fill with no visible event. If assistance is applied at claim time rather than tracked as a portfolio, the exhausted grant is discovered at the moment the next shipment should go out, and the therapy pauses.

Accreditation evidence fails the same way. Quality measures, patient management activity, complaint handling and outcomes get assembled in a scramble before survey, which is both expensive in senior time and visible to an experienced surveyor, because retroactively reconstructed evidence looks exactly like what it is. Compute the measures continuously from the operational record so preparing for survey is reviewing numbers that are already true. Both features are unglamorous, both are cheap relative to their value, and both get cut first when a budget tightens.

Should you build custom or configure what you already own?

Configure if you are a retail or community pharmacy with a small specialty tail, or a single site handling a handful of therapies. Your dispensing system plus disciplined process will beat a build, and the accreditation burden at that scale is genuinely manageable by hand. Spending on a coordination platform there buys structure you do not yet need.

Be fair about the incumbents rather than dismissive. Therigy exists precisely because dispensing systems did not carry clinical management, and it does that job. WellSky CareTend and Inovalon ScriptMed carry dispensing and billing depending on the pharmacy's history. The market is fragmented because the business grew from two different roots, retail dispensing and clinical case management, and each vendor added the missing half rather than rethinking the record. That is a structural observation your own team can verify by counting how many applications a pharmacist opens for one patient.

Build when two or more hold. You have limited distribution contracts with manufacturer reporting obligations and an analyst producing them by hand. Clinical management and dispensing are in different systems and staff work in both. Nobody can tell you today which patients have been waiting longest and why. Financial assistance lapses are interrupting therapy. Or you are adding therapies faster than your vendor can configure them. If your staff are effectively the integration between two products, that is the work a build removes.

How do hidden costs get into the quote?

Five drivers, all identifiable before signing.

• Manufacturer contract count. Each reporting obligation is a field map, validation rules and a delivery channel, and every contract has its own field layout and cadence.
• Dispensing scope. Whether dispensing and claim adjudication are in scope or stay in your existing system is the largest single lever on the total.
• Therapy specific clinical programmes. Each one carries its own assessment content, schedule and escalation rules, so ten therapies is not one workflow with a dropdown.
• Portal work. Where no electronic path exists, the design has to make manual steps first class, and that modelling is real work rather than an omission.
• Infusion services. Nursing visit scheduling and supply management is a different operational model again and should be scoped as its own phase.

The cost that surprises people is clinical content authoring. Assessment questions, intervention protocols and escalation rules have to be written by your pharmacists, and that is calendar time from people who are already fully committed. Name them at kickoff and protect the hours, because content is the usual reason these projects arrive late rather than engineering.

What separates a build that works from one that fails here?

The builds that work make the patient therapy journey the primary record. Referral intake creates it, and benefits, prior authorisation, financial assistance, clinical assessment and shipment readiness are gates on it, each with a status, an owner and a timestamp. The operational view is a list ordered by days since referral with the blocker named, so the team works the oldest and most stuck first rather than whatever is on top of the fax pile. Document extraction earns its place at intake, turning a faxed referral into structured patient, prescriber, diagnosis and insurance fields with a human confirming low confidence reads, because those hours sit at the front of the clock where delay costs most.

The second differentiator is whether manufacturer reporting is configuration or code. Each contract should hold a field map from your internal data model to the manufacturer's expected fields, plus a schedule, a delivery channel and validation rules, so adding a manufacturer means defining a map that your own analyst can define. If every new contract requires a developer, you have moved the bottleneck rather than removed it. Keep a record of exactly what was sent and when, because manufacturers do query figures from prior quarters after the underlying data has been corrected.

When choosing a developer, ask them to model the therapy journey before quoting. Ask how financial assistance is tracked between fills, and reject an answer that applies it at claim time. Ask how a new manufacturer report gets added. Ask which dispensing systems and hub portals they have worked with by name. Then settle ownership of the code, the cloud accounts and your clinical content and field maps in writing, because those represent years of accumulated operational knowledge and should never be trapped in a supplier's configuration.